MAPK inhibitors (MAPKi) show outstanding clinical response rates in melanoma patients harbouring BRAF mutations, but resistance is common. High-throughput, subcellular proteome analyses at two differe
The decision on starting a diagnostic trajectory for dementia is considered a preference-based decision since the considerations and values of patients regarding the timing of...
